News | April 30, 2021

President Biden Signs The Advancing Education On Biosimilars Act Into Law

Bipartisan Legislation Aims to Lower Health Care Costs Through Bolstering Biosimilars Education

Biosimilars Forum Executive Director Meaghan Rose Smith issued the following statement after President Biden signed the Advancing Education on Biosimilars Act into law:

The Biosimilars Forum thanks President Biden for his swift action in signing the Advancing Education on Biosimilars Act into law and looks forward to continuing to work with the administration to ensure that patients and providers have all of the educational resources and materials they need to be assured of the safety and efficacy of biosimilars. These life-saving drugs and their cost-savings capabilities can play a key role in the nation’s path to economic recovery, with the potential to save the U.S. up to $100 billion over the next five years, but only if their use increases. As the administration approaches its 100th day in office, we encourage them to continue to prioritize smart policy solutions that will increase stakeholder confidence and access to biosimilars while lowering costs for the entire health care system. We commend the bipartisan leadership of Senator Hassan, Senator Cassidy, and Congressman Bucshon for their help to combat rising health care costs.

The FDA has identified education as an important factor for the successful adoption of biosimilars, recognizing the need to increase public awareness in the Biosimilars Action Plan. This bipartisan legislation will provide educational materials and programs to patients and providers that demonstrate the safety and effectiveness of approved biosimilars, improving confidence in these medicines to increase use of them and drive health care savings.

The members of the Biosimilars Forum represent the majority of companies with the most significant U.S. biosimilars development portfolios. The Biosimilars Forum works to collaborate with partners to help improve awareness and access to biosimilars. For more information on the Biosimilars Forum or the policy proposals it supports, visit or

Source: Biosimilars Forum